BioCardia, Inc. BCDA
BioCardia, Inc. (Nasdaq: BCDA) is a cardio-renal-metabolic drug developer. Its lead program, CardiAMP Cell Therapy (BCDA-01), is in Phase 3 for Ischemic heart failure with reduced ejection fraction (HFrEF). Its next catalyst on record is CardiAMP Cell Therapy System: BioCardia targets treatment of first patients in Japan and realization of commercial revenues in 2028. (2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CardiAMP Cell Therapy System — BioCardia targets treatment of first patients in Japan and realization of commercial revenues in 2028. (2028). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CardiAMP Cell Therapy HF II (BCDA-01) | Ischemic HFrEF | cell therapy | Phase 3 |
| CardiAMP Cell Therapy CMI (BCDA-02) | Chronic myocardial ischemia with refractory angina | cell therapy | Phase 3 |
| CardiALLO allogeneic MSC (BCDA-03) | Ischemic HFrEF | cell therapy | Phase 2 |
| PulmALLO allogeneic MSC | Acute respiratory distress syndrome | cell therapy | Pre-clinical |
Recent results and decisions
- Nov 6, 2026n/a BioCardia completed clinical consultation process with Japan's PMDA for CardiAMP Cell Therapy System, advancing toward submission of marketing approval application.
With the completion of consultations with PMDA regarding our application materials, we are closer to the day when we can provide CardiAMP cell therapy to heart failure patients in Japan.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.